Vaccitech Announces Late-Breaker Abstract Accepted for Presentation at AASLD - The Liver Meeting® Providing Update on the Phase 1b/2a Study of VTP-300
Source:
Nasdaq GlobeNewswire
/
02 Nov 2022 08:00:02 America/New_York
N/A
Share on,